Topic: Policy

  • Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019

  • Fact Checking the NYT Fact Check on the Trump Proposal

  • Understanding the Rewards of Successful Drug Development: Thinking Inside the Box

  • Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

    Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

  • Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries

  • List Price, Net Price, and the Rebate Caught in the Middle

  • Perspective on National Coverage Analysis of CAR-T Therapies

    Perspective on National Coverage Analysis of CAR-T Therapies

  • DPL responds to HHS Blueprint (May 16, 2018)

  • Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold

    Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold

  • Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?

    Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?